Biotime-Nasdaq's best kept secret? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotime-Nasdaq's best kept secret?

BTIM 0.0001000

0.0%

Nov 5 1:26 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: William Nguyen who wrote ()	6/2/1998 10:21:00 AM
From: Craig McNeill	Read Replies (1) of 1432

<offtopic> Baxter suspends blood substitute trials: DEERFIELD, Ill., June 2 (Reuters) - Baxter International Inc. BAX.N said Tuesday it had suspended the European clinical trial of its HemAssist blood substitute in patients suffering from severe trauma. The medical products maker said it suspended the trial, which had enrolled 117 patients, to further analyze data gathered and assess the efficacy of HemAssist. Baxter said the decision will delay its ability to receive marketing clearance for the product in the U.S. or Europe, which it had been expecting by late 1999 or early 2000 "Baxter will continue to work with its clinical investigators and the European regulatory authorities to determine its options," said the company. In March, Baxter halted a U.S. Phase III clinical trial of with HemAssist in severe trauma cases. Phase III trials in the United States with patients undergoing elective surgery continue to add patients, Baxter said."In previous clinical trials, more than 500 patients have received HemAssist and its safety profile has been well-established," the company said.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next